Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Adamis Pharmaceuticals Corporation (ADMP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1985-0.0266 (-11.82%)
At close: 04:00PM EDT
0.2051 +0.01 (+3.32%)
After hours: 07:30PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close0.2251
Open0.2300
Bid0.2050 x 2200
Ask0.1988 x 800
Day's Range0.2000 - 0.2329
52 Week Range0.1800 - 1.4800
Volume921,286
Avg. Volume699,414
Market Cap29.772M
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-0.2730
Earnings DateNov 21, 2022 - Nov 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.42
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ADMP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adamis Pharmaceuticals Corporat
    Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
    Rating
    Fair Value
    Economic Moat
    11 days agoMorningstar
View more
  • Benzinga

    Adamis Pharma Shares Nosedive As Its COVID-19 Candidate Shows No Efficacy

    Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19 infection. The trial did not achieve its primary endpoint, as measured by comparing the rate of sustained clinical resolution of symptoms of COVID-19 at day 14 of Tempol versus placebo. Last year, the company started dosing in the Phase 2/3 trial for Tempol, which was designed to enroll 248 patients. Th

  • GlobeNewswire

    Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

    Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo Independent Data Safety Monitoring Board recommends halting the trial SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the third planned interim analysis of the Phase 2/3 clinical trial examining the effects of Tempol in high risk subjec

  • GlobeNewswire

    Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

    The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects Independent Data Monitoring Board to review interim data from approximately 200 initial subjects SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the initial planned enrollment of 248 subjects. “We are very

Advertisement
Advertisement